Raymond James initiated coverage on INmune Bio with a new price target

9/27/24 7:36:48 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Raymond James initiated coverage of INmune Bio with a rating of Outperform and set a new price target of $18.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INMB

Date	Price Target	Rating	Analyst
1/28/2025	$23.00	Buy	Rodman & Renshaw
10/21/2024	$20.00	Buy	Alliance Global Partners
9/27/2024	$18.00	Outperform	Raymond James
8/22/2024	$22.00	Sector Outperform	Scotiabank
6/1/2023	$16.00	Outperform	Robert W. Baird
5/24/2022	$14.00 → $7.00	Buy → Neutral	B. Riley Securities
1/24/2022	$32.00 → $20.00	Buy	B. Riley Securities
7/7/2021	$32.00 → $42.00	Buy	Maxim Group